RICTOR/mTORC2 downregulation in BRAFV600E melanoma cells promotes resistance to BRAF/MEK inhibition

RICTOR/mTORC2 downregulation in BRAFV600E melanoma cells promotes resistance to BRAF/MEK inhibition

Abstract Background The main drawback of BRAF/MEK inhibitors (BRAF/MEKi)-based targeted therapy in the management of BRAF-mutated cutaneous metastatic melanoma (MM) is the development of therapeutic resistance. We aimed to assess in this context the role of mTORC2, a signaling complex defined by the...

Full description

Bibliographic Details
Main Authors: Luca Ponzone, Valentina Audrito, Claudia Landi, Enrico Moiso, Chiara Levra Levron, Sara Ferrua, Aurora Savino, Nicoletta Vitale, Massimiliano Gasparrini, Lidia Avalle, Lorenza Vantaggiato, Enxhi Shaba, Beatrice Tassone, Stefania Saoncella, Francesca Orso, Daniele Viavattene, Eleonora Marina, Irene Fiorilla, Giulia Burrone, Youssef Abili, Fiorella Altruda, Luca Bini, Silvia Deaglio, Paola Defilippi, Alessio Menga, Valeria Poli, Paolo Ettore Porporato, Paolo Provero, Nadia Raffaelli, Chiara Riganti, Daniela Taverna, Federica Cavallo, Enzo Calautti
Format: Article
Language:English
Published: BMC 2024-05-01
Series:Molecular Cancer
Subjects:
mTORC2
RICTOR
NAMPT
Drug resistance
Targeted therapy
BRAFV600E melanoma
Online Access:https://doi.org/10.1186/s12943-024-02010-1

Internet

https://doi.org/10.1186/s12943-024-02010-1

Similar Items